NASDAQ •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 05/18/2026 16:00
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization4,347.77 mln
Float40.29 mln
Earnings Date07/28/2026
EPS
0.91
Stretched
P / E
58.95
Richly valued
Piotroski F-Score
8
/ 9
Very strong
Beneish M-Score
-3.29
Reliable
1-Year Forecast
63.50
Attractive
Relative Strength
21
/ 100
Significantly lagging
Business Description
Kiniksa Pharmaceuticals International plc is a London-based company focused on bringing new treatments to patients with rare and chronic inflammatory conditions. Its main product, ARCALYST, is approved for recurrent pericarditis, a painful and recurring inflammation of the lining around the heart. The company is also advancing two additional drug candidates through early and mid-stage clinical development, both targeting similar inflammatory diseases. Originally founded in 2015, Kiniksa operates across the United States, the United Kingdom, and other international markets.
